GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.

Direct download: GRACEcast-112_Lung-Video_ASCO_2012_Socinski_4.m4v
Category:Lung-Cancer-Video -- posted at: 6:01pm PDT

Dr. Mark Socinski reviews key results in small cell lung cancer (SCLC) from ASCO 2012, including the SWOG 0802 trial of topotecan +/- VEGF inhibitor aflibercept and a Japanese randomized trial of cisplatin/amrubicin vs. cisplatin/irinotecan.

Direct download: GRACEcast-112_Lung-Audio_ASCO_2012_Socinski_4.mp3
Category:Lung-Cancer-Audio -- posted at: 6:00pm PDT

Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.

Direct download: GRACEcast-111_Lung-Video_ASCO_2012_Socinski_3.m4v
Category:Lung-Cancer-Video -- posted at: 8:46pm PDT

Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.

Direct download: GRACEcast-111_Lung-Audio_ASCO_2012_Socinski_3.mp3
Category:Lung-Cancer-Audio -- posted at: 8:45pm PDT

Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

Direct download: GRACEcast-110_Lung-Video_ASCO_2012_Socinski_2.m4v
Category:Lung-Cancer-Video -- posted at: 12:44am PDT

Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

Direct download: GRACEcast-110_Lung-Audio_ASCO_2012_Socinski_2.mp3
Category:Lung-Cancer-Audio -- posted at: 12:43am PDT

Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.

Direct download: GRACEcast-109_Lung-Video_ASCO_2012_Socinski_1.m4v
Category:Lung-Cancer-Video -- posted at: 3:14pm PDT

Dr. Mark Socinski from the University of Pittsburgh reviews the survival benefit and implications from the PARAMOUNT maintenance therapy trial of Alimta (pemetrexed) in advanced NSCLC.

Direct download: GRACEcast-109_Lung-Audio_ASCO_2012_Socinski_1.mp3
Category:Lung-Cancer-Audio -- posted at: 3:13pm PDT

Dr. Stephanie Harman, Director of Palliative Care at Stanford University Medical Center, reviews the challenges of depression and fatigue related to cancer, and treatment approaches for these issues.


Dr. Stephanie Harman, Director of Palliative Care at Stanford University Medical Center, reviews the challenges of depression and fatigue related to cancer, and treatment approaches for these issues.